PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") to develop an integrated, AI-navigated, ...
Vietnam Investment Review on MSN
PRISM BioLab and Receptor AI partner on drug discovery
TOKYO, March 13, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") ...
Managing complex medical conditions often requires the simultaneous use of multiple different drugs, referred to as polypharmacy. While necessary, this significantly increases the risk of drug-drug ...
Scientists have discovered a new generation of angiotensin receptor blockers that may be used to treat coronavirus disease 2019 (COVID-19). In silico docking and molecular dynamics studies have shown ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center Androgen receptor pathway ...
Neuroinflammation drives the progression of neurodegenerative disorders like Alzheimer's, Parkinson's, and multiple sclerosis ...
Rystiggo (rozanolixizumab) is a brand-name subcutaneous infusion that’s prescribed for myasthenia gravis. Rystiggo has interactions with some other drugs. Examples include immunoglobulins and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results